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Abstract
Phage integrases catalyze site-specific, unidirectional recombination between two short att
recognition sites. Recombination results in integration when the att sites are present on two
different DNA molecules and deletion or inversion when the att sites are on the same molecule.
Here we demonstrate the ability of the φC31 integrase to integrate DNA into endogenous
sequences in the mouse genome following microinjection of donor plasmid and integrase mRNA
into mouse single-cell embryos. Transgenic early embryos and a mid-gestation mouse are reported.
We also demonstrate the ability of the φC31, R4, and TP901-1 phage integrases to recombine two
introduced  att  sites on the same chromosome in human cells, resulting in deletion of the
intervening material. We compare the frequencies of mammalian chromosomal deletion catalyzed
by these three integrases in different chromosomal locations. The results reviewed here introduce
these bacteriophage integrases as tools for site-specific modification of the genome for the creation
and manipulation of transgenic mammals.
Background
The ability to manipulate the mammalian genome in vivo
is important in many areas of research. There is a growing
need for site-specific recombinases that function in the
mammalian environment to catalyze genomic integration
and excision, for example in the construction of trans-
genic organisms and the study of gene function in vivo.
The site-specific integrases of bacteriophages φC31, R4,
and TP901-1 have been shown to function in human and
mouse cells to catalyze excision on extrachromosomal
vectors and chromosomal integration [1–4]. Phage φC31
integrase has been applied to achieve chromosomal inte-
gration in gene therapy studies [5–9]. These results sug-
gested that these site-specific integrases would likely
function in the mammalian embryonic environment and
could have utility in the creation of transgenic animals
and manipulation of the mammalian genome in vivo. The
use of bacteriophage integrases in mammalian transgene-
sis is a new field. This article will discuss some of the
potential applications of site-specific integrases in this
area and the preliminary results our lab has obtained to
date.
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Site-Specific Integration for the Construction of 
Transgenic Mammals
Transgenic mammals are an essential component of bio-
technology, having a wide variety of applications ranging
from gene knockout studies to serving as living bioreac-
tors. A common method of transgenic mammal produc-
tion relies on microinjection of DNA directly into the
pronucleus of a single-cell embryo, with genomic inser-
tion generally resulting by random integration. Alterna-
tively, mouse embryonic stem (ES) cells can be modified
by homologous recombination and placed into a devel-
oping embryo. The latter approach results in a mosaic ani-
mal that may or may not have germ cells modified.
Random integration and homologous recombination
both occur at low frequencies (10-4 and 10-6, respectively).
Other methods have been developed for DNA delivery
and maintenance in ES cells including mammalian artifi-
cial chromosomes [10,11], retroviruses [12–14], and the
Sleeping Beauty transposon [15]. Nuclear transfer from
more mature cells can also be used to introduce a new
genome for a developing embryo, and this nuclear DNA
can be first modified by any of the above methods
[16,17].
The available technologies are hindered in that gene inser-
tion is often random. In the resultant transgenic animals,
the expression levels of the genes of interest are influenced
by context factors that are difficult to control. For exam-
ple, some influencing factors include the regulatory and
bacterial elements in the insertion construct itself [18], the
position of the insertion in the genome [19], and the
number of integrated constructs [19,20]. Production of a
desired clone often takes many rounds of screening. Fol-
lowing screening there may be additional problems
caused by the transgene insertion resulting in sterility or
pre-adolescent lethality, preventing preservation of the
newly developed strain. Efficient, targeted single copy
integrations would be helpful for the improvement of
transgenic animal production. Site-specific integration
systems could potentially be useful in this context. A bac-
teriophage integrase, such as that of phage φC31, can be
used to integrate a donor plasmid into the mammalian
genome, and integrants can be screened by a simple PCR
reaction to identify integrations into known and desirable
targets. A quantitative PCR approach can be used to
ensure that only single integration events are selected. In
the creation of multiple transgenic animal lines, candidate
clones can be screened and selected so that the genomic
integration event in each animal line is in the identical
genomic location and orientation, thereby eliminating
positional effect differences between the different trans-
genic lines. Any genomic location is likely to exert context
effects that affect the expression of an integrated trans-
gene, but the use of a site-specific integration system will
help to ensure that these effects are not varied among dif-
ferent lines. To date, site-specific recombinases have not
been used for the creation of transgenic mammals, though
some, such as Cre, have been valuable for genomic
manipulations in transgenic animals, as discussed below.
Phage Integrase Biology in the Mammalian Environment
Members of the serine family of site-specific recombinases
[21], including integrases from phages φC31 [1,2,5,6,9],
R4 [3], and TP901-1 [4], are good candidates for mamma-
lian genomic modification. In nature, each integrase rec-
ognizes a sequence in the phage genome, the phage
attachment site attP. Each integrase also recognizes a bac-
terial attachment site, attB, in the bacterial genome. Inte-
grases of the serine family of recombinases are capable of
recombining these short attP and attB attachment sites,
whose minimal sizes are 35–50 bp. The products, two
hybrid sites, attL and attR, are no longer substrates for
recombination by the integrase, so the reactions are unidi-
rectional [22]. While the integrase alone can only catalyze
a recombination between an attP  and an attB site, the
result of the recombination can vary based on the location
and orientation of these two att sites. When located on
different DNA molecules, recombination between an attP
and an attB results in an integration event. However, if the
two sites are located on the same DNA molecule (plasmid
or chromosome), two outcomes are possible: if the attP
and the attB are in the same orientation on the DNA, the
net result will be a deletion event; if the two att sites are in
opposite orientations, the net result will be an inversion.
Thus, by knowing the locations and orientations of com-
patible att sites, specific recombination events can be cre-
ated and selected for.
We have demonstrated that the φC31 integrase is able to
mediate efficient integration of attB-bearing plasmids into
the human and mouse genomes, at inserted wild-type attP
sites and at endogenous "pseudo" attP sites that have par-
tial identity to attP  [2]. We previously identified 26
pseudo attP sites in the human genome, and 57 pseudo
attP sites in the mouse genome [2]. We have not detected
the presence of pseudo attB sites in mammalian genomes,
which should reduce the likelihood that endogenous
genomic sequences are inadvertently deleted during an
integration attempt. There may not be pseudo attBs that
could be recognized and recombined with a pseudo attP
by the integrase.
Site-Specific Chromosomal Deletions
In addition to chromosomal integration events, often
times a chromosomal deletion is desired, such as in the
generation of knockout transgenic animals. One way to
accomplish deletion of a sequence of interest is through
the use of site-specific recombinases, such as the Cre
recombinase of coliphage P1 and its loxP recognition sites
[23]. The deletion can be precisely confined to a specificReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/79
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developmental time or tissue, based on control of recom-
binase expression. This outcome is most commonly
achieved by creating a transgenic mouse that contains the
gene of interest flanked by loxP sites, and then crossing
that mouse with a Cre-expressing mouse [24]. The Cre
gene may, for example, be under a tissue-specific pro-
moter. Once crossed, the gene of interest will be deleted in
all cells in which Cre is expressed, thereby generating a tis-
sue-specific knockout [24–30]. The same approach can be
used to activate a gene of interest, by inserting a stop cas-
sette between the promoter and the gene of interest and
flanking the stop cassette with loxP sites [31]. If the gene
knockout is desired in the entire animal, the "floxed"-
transgene mouse oocytes can be transfected with a Cre-
expression plasmid or Cre mRNA, so that expression is
transient, but sufficient to delete the gene of interest at an
early developmental stage, thereby producing an animal
devoid of the gene of interest [32,33].
Alternatively, excision can be controlled in a temporal-
specific manner by expressing Cre from an inducible pro-
moter. A fusion protein of Cre recombinase and a
mutated hormone-binding domain of the murine estro-
gen receptor showed temporal-specific activity in trans-
genic mice that was controlled by the presence of
tamoxifen [34]. Temporal-specific recombination has also
been accomplished by driving Cre expression from induc-
ible promoters, such as a tetracycline-inducible promoter
[35]. Simultaneous temporal- and tissue-specific Cre
expression has been demonstrated using tissue-specific
promoters to drive expression of the Cre ORF fused to a
hormone receptor ligand-binding domain [29,36].
Some circumstances require more complicated deletion/
insertion events, such as sequential gene inactivation and
exon swapping [37]. Additionally, it may be desirable to
remove extraneous sequences in an integrated vector, such
as bacterial or mammalian drug selection markers [18].
The FLP recombinase from the 2 µm plasmid of S. cerevi-
siae has been used in transgenic mice as an alternative to
Cre [38,39] and in combination with Cre [40], although
FLP functions at only ~10–25% efficiency compared to
Cre in generating chromosomal deletions [41]. The Cre
and FLP recombinases are the only two enzymes currently
available for genomic manipulation experiments, making
complicated experimental schemes difficult to perform
[25,40]. The increasing desire to perform complex
genomic manipulations creates a need for additional site-
specific recombinase tools that function efficiently in the
mammalian chromosomal environment.
Results
Phage φC31 Integrase Functions in the Mouse Embryonic 
Environment and Mediates Genomic Integration
To demonstrate that the φC31 integrase would be func-
tional in the embryonic environment, single-cell embryos
of the FVB/NacfBR mouse strain were injected with 3 ng/
µl nucleic acid solutions directly into the pronucleus. Two
groups of injected embryos were studied. One group
received pCMVInt plasmid DNA [1] as a source of inte-
grase (n = 31), and the other received φC31 integrase
mRNA (n = 32). Both groups were co-injected with the
intramolecular-integration assay vector pBCPB [1] carry-
ing attB and attP sites. The embryos were frozen at the
two-cell stage, total DNA was extracted [42], and the
expected wild-type attL junction was PCR amplified from
recombined plasmid. A product of correct size was
observed in both groups of embryos. This product is spe-
cific for the recombination event and is not present unless
φC31 integrase is expressed [1]. Embryos co-injected with
integrase mRNA produced a band of correct size with just
~25% of the template that was required to detect the same
band from the pCMVInt/pBCPB injections. This result
suggested that integrase mRNA was more efficient in the
embryonic environment than DNA, presumably due to
the elimination of the requirement for transcription. This
result was consistent with observations that injection of
Cre mRNA into mouse oocytes provided efficient Cre
activity in vivo [33]. The use of mRNA instead of DNA also
precluded undesirable integration of the integrase gene by
random integration.
Phage φC31 integrase can efficiently catalyze a site-specific
cassette exchange reaction using introduced wild-type att
sites in mouse ES cells [43] and can recognize and insert
attB-containing plasmids into pseudo attP  sites in the
murine genome [2,6]. A hotspot for φC31 integrase-medi-
ated integration was identified in hepatocytes on chromo-
some 2 (GenBank: AC 079573) and named mpsL1
(mouse pseudo attP site in liver) [6]. Integration at mpsL1
was also detected in mouse NIH3T3 cells [2], indicating
that mpsL1 may be a preferred integration site in the
mouse genome. A GFP vector, pEGFPB2, carrying an attB
site was injected into one-cell embryos either with (n =
35) or without (n = 27) φC31 integrase mRNA. GFP
expression was used to indicate visually the number of
embryos with integrated DNA, because non-integrated
DNA should be gradually lost during a 5 day period of
rapid cell division to the multi-cell or blastocyst stage. By
fluorescent microscopic analysis, the two groups had sim-
ilar numbers of detectibly GFP-positive embryos, 6/35
with integrase and 5/27 without integrase. Embryos were
positive for GFP expression in all cells; however, the group
that received the integrase mRNA contained embryos with
an overall more intense green fluorescence.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/79
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DNA extracted from the embryos injected with pEGFPB2
with and without φC31 integrase mRNA was used as a
template in a PCR assay designed to amplify the attL junc-
tion produced when φC31 integrase mediated site-specific
integration at mpsL1. The group that received φC31 inte-
grase mRNA produced a band of predicted size that was
subsequently cloned and sequenced. The DNA sequence
from the PCR product, shown in Figure 1A, demonstrated
φC31 integrase-mediated site-specific integration at
mpsL1 and proved that site-specific integration occurred
within the embryonic genome. No integration into
mpsL1 was detected in the GFP-positive embryos that did
not receive integrase.
Construction Of Site-Specific Integrant Transgenic 
Animals
FVB/NacfBR single-cell embryos were injected with an
attB-bearing donor plasmid, pBChFIXattB [6], with or
without  φC31 integrase mRNA. Injected embryos were
implanted into surrogate mothers at ~20 embryos per ani-
mal. Pups were harvested mid-gestation at approximately
2 weeks post-implantation, and genomic DNA was iso-
lated and screened for integrated donor plasmids by PCR.
To determine whether an animal contained an integrated
donor vector, PCR was employed to amplify a 406-bp
internal hFIX fragment of the donor plasmid. To deter-
mine whether donor vector was integrated site-specifically
by a φC31-mediated event, PCR primers were designed to
distinguish an intact attB, signifying random integration,
from an attL, signifying φC31-mediated integration. Ani-
mals whose DNA produced a 406-bp donor band but not
an intact attB band were likely to have site-specifically dis-
rupted the attB sequence, indicating an integrase-medi-
ated event (Table 1).
A mid-gestation mouse found to have a plasmid inserted
site-specifically in its genome was further studied by PCR
and sequence analysis. Using a nested PCR rescue tech-
Integration at mouse genomic sequences Figure 1
Integration at mouse genomic sequences. (A) Sequence from an embryo-derived PCR clone displays the characteristic site-spe-
cific crossover between the attB arm, shown in gray, and the murine pseudo attP site, mpsL1, with the TT core (in bold) 
located at the point of crossover. A one-base mismatch (underlined) located downstream of the crossover event may be a pol-
ymorphism between the mouse FVB/NacfBR strain and the C57Bl/6 strain that was sequenced in the database. (B) Comparison 
of the sequences of embryo-derived pseudo attP sites mpsL1 and mpsT1 with the wild-type φC31 attP. The common TT core 
is shown in bold. Both of these embryo-derived pseudo attP sites are ~30% identical to the wild-type φC31 attP. The matching 
base pairs with a 40 base attP are shown in gray.
Table 1: FVB/NacfBR transgenics obtained following injection with attBhFIX-containing vector with or without φC31 integrase mRNA.
ng/µl attB DNA/
Integrase mRNA
Embryos injected Embryos implanted Pups harvested hFIX positive φC31-mediated
3 DNA + 0 mRNA 68 48 16 0 0
3 DNA + 3 mRNA 144 102 39 3 1
3 DNA + 6 mRNA 415 284 66 1 0
A.
attB GCGGTGCGGGTGCCAGGGCGTGCCCTT
Embryo GCGGTGCGGGTGCCAGGGCGTGCCCTTGATACCCAAAGGCCCTATTAATTTAGG
mpsL1 TCTGAGTAGTACCCTGGCTTTCCTATTGACACCCAAAGGCCCTATTAATTTAGG
B.
mpsL1 TAGTACCCTGGCTTTCCTATTGACACCCAAAGGCCCTATT
mpsT1 CTCCACCACAAGGTTTCCATTAGAAAAGCCCCGGCTCCCA
attP GCCCCAACTGGGGTAACCTTTGAGTTCTCTCAGTTGGGGGReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/79
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nique [2], it was determined that this animal contained
the donor plasmid site-specifically integrated into a
sequence on chromosome 4 termed mpsT1 (mouse
pseudo attP site in Transgenic 1), shown in Figure 1B. This
integration site is located in the last intron of a putative
gene detected in a 16-day neonate (Genbank: AK052928).
The integration event did not prevent embryogenesis in
this experiment, indicating that an integration event at
mpsT1 was unlikely to disrupt development and this loca-
tion was potentially a suitable target site for future trans-
gene integrations. Like the mpsL1 pseudo site, mpsT1 has
limited identity to the wild type attP sequence (Figure 1B).
Chromatin structure may influence which pseudo sites are
used [6]. Repeatedly targeting an identical genomic locus
such as mpsT1 could allow for the creation of multiple
transgenic lines with transgenes integrated at the same,
predictable genomic locus. Creation, by directed evolu-
tion [44], of integrases with tighter site-specificity may
allow for such a possibility.
The use of an engineered mouse strain containing an
inserted wild-type attP site could help resolve position
effects by providing a method to preferentially target
transgenes to a predetermined location. The use of an attP
transgenic mouse strain might also increase the integra-
tion frequency, because the integrase might work more
efficiently at a perfect attP site, compared to pseudo attP
sites. The detection of site-specific integrants would also
be simplified because the sequence of the target site was
known. Therefore, similar experiments were performed
on a strain of transgenic mice we prepared that contained
a wild-type φC31 attP site. Injections into this attP-bearing
mouse strain were performed with φC31 mRNA and the
attB donor plasmid pBChFIXattB. Of 7 injected pups that
carried the wild-type attP site, none were found to have an
insertion of the attB  donor plasmid anywhere in their
genomes. Although the number of pups examined was
low, this negative result may indicate a poor genomic
location of the φC31 attP site in this transgenic strain, with
respect to chromatin access for the φC31 integrase. The
creation of a strain with a more accessible attP site might
result in a higher percentage of φC31-mediated integra-
tions at the attP site.
Chromosomal Deletions Catalyzed by Phage Integrases
The integrases of phages φC31, R4, and TP901-1 function
efficiently in mammalian cells to complete precise dele-
tions on extrachromosomal introduced DNA [1–4]. It was
recently shown that the φC31 integrase could perform
intrachromosomal deletions at a frequency ~10% that of
Cre [41]. Addition of a nuclear localization signal (NLS)
to φC31 integrase increased this frequency to ~80% of that
of Cre [41]. The ability of R4 and TP901-1 integrases to
catalyze chromosomal deletions was unknown. To facili-
tate their use as genomic tools, it would be useful to have
a direct comparison of chromosomal deletion activity
among these site-specific integrases. To determine the fre-
quency of chromosomal deletions catalyzed by these inte-
grases, we established human cell lines with an integrated
copy of a vector containing the φC31, R4, and TP901-1
attB and attP recognition sites (Figure 2). Transfection of
these cells lines with integrase expression plasmids, fol-
lowed by quantitative PCR and Southern analysis,
allowed us to calculate the chromosomal deletion fre-
quency of each integrase. Because all three recognition site
pairs were in the same vector, and thus in the same chro-
mosomal context in each cell line, we were able to obtain
a directly comparable measure of the chromosomal dele-
tion frequency mediated by the φC31, R4, and TP901-1
integrases.
Mammalian expression vectors were created for each of
the three integrases (Figure 2), in which the cytomegalovi-
rus immediate early (CMV) promoter drove expression of
the integrase, followed by an internal ribosome entry site
(IRES), and the gene for green fluorescent protein (GFP).
Cell lines were transfected with a pInt-I-hrGFP vector, and
GFP-positive cells were sorted 72 h post-transfection,
expanded, and genomic DNA was prepared. Separately for
each sample, the total integrated vector copy number was
determined by quantitative amplification of a region of
the hygromycin resistance gene. The number of deletion
products was determined by quantitative amplification of
attR junctions. Deletion frequency was calculated as the
ratio of attR junctions to total vector copies. The results are
shown in Figure 3A.
Quantitative PCR analysis of TP901-1 integrase-catalyzed
deletion was unsuccessful. The TP901-1 attR  is highly
A+T-rich, making Taqman primer/probe design difficult.
Because we could not accurately determine TP901-1 dele-
tion frequency by qPCR, Southern blot analysis was per-
formed. This analysis was done for φC31 and R4 as well,
in order to directly compare with the TP901-1 frequency
and to independently verify the deletion frequency deter-
mined by qPCR. Genomic DNA from integrase-trans-
fected cell lines was analyzed by Southern blot, and
deletion frequency was quantified. Chromosomal recom-
bination resulted in reduction of the genomic vector by
deletion of 4.8 kb (φC31), 3.7 kb (R4), or 4.2 kb (TP901-
1) of intervening vector sequence. Representative South-
ern blots of φC31-, R4-, and TP901-1-transfected cell line
genomic DNA are shown in Figure 3B. Quantification of
band intensity indicated that Southern analysis of chro-
mosomal deletion frequency was in agreement with that
calculated by qPCR analysis for the φC31 and R4-trans-
fected cell lines.
The  φC31 integrase consistently performed more effi-
ciently than the R4 and TP901-1 integrases. In cell lineReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/79
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293-3BP3, chromosomal deletion was catalyzed by the
φC31 integrase with an average frequency of 51%, by the
R4 integrase at an average frequency of 37%, and by the
TP901-1 integrase at a frequency of 39%. The R4 and
TP901-1 integrases performed equally well, though at a
lower frequency than the φC31 integrase, in cell line 293-
3BP6. The frequency of deletion catalyzed by the φC31
and R4 integrases was lower in all other cell lines to
varying degrees, while TP901-1 integrase showed no
measurable activity in these other cell lines.
The chromosomal deletion frequency of the φC31 inte-
grase ranged from 51% in cell line 293-3BP3 to only 1.7%
in the 293-3BP8 cell line. Similar ranges were observed for
the R4 integrase. These variations in activity most likely
represented a chromosomal position effect of the inte-
grated vectors in different regions of the genome, which
may affect the ability of the integrase to efficiently access
the att sites. We have hypothesized that the φC31 integrase
preferentially integrates into pseudo attP sites that are in
actively expressed regions; an open chromatin configura-
tion may be required for efficient targeting and recombi-
nation by the integrase [6]. This hypothesis was supported
by the apparent chromosomal position effects on excisive
recombination observed here. The TP901-1 integrase
appeared to be even more susceptible to chromosomal
position effects, as evidenced by its ability to perform
deletions at ~35% efficiency in two of the cell lines, the
two with the highest deletion frequencies by φC31 and R4
integrases, but its lack of deletion formation in the other
cell lines analyzed.
Discussion
The experiments reported here suggest that the φC31 inte-
grase can be used to create transgenic mice carrying site-
specific transgene insertions. The numbers of φC31-medi-
ated transgenic animals generated were low, with approx-
imately 2.6% of harvested pups representing φC31
integrase-mediated transgenic animals, in the best experi-
ment. Our sequence data demonstrated that the φC31
integrase functioned in the embryonic nuclear environ-
ment to integrate plasmid DNA site-specifically into the
genome. Additional experiments with greater numbers of
animals will be required to optimize the procedure and
determine the efficiency of such an approach for generat-
ing transgenic mammals. Such a tool would be beneficial
because the genomic location of the integration site,
either at an inserted wild-type attP  site or at a known
endogenous pseudo attP site, can be specifically detected
by PCR amplification, potentially allowing the creation of
multiple transgenic lines with different integrated trans-
genes in the same genomic context. This feature would
permit creation and comparison of multiple transgenic
animal strains without confounding chromosomal posi-
Chromosomal deletion analysis system Figure 2
Chromosomal deletion analysis system. Plasmid p3BP was linearized and integrated into the genome of 293 cells. AttB and attP 
sites for φC31, R4, and TP901-1 integrases are indicated. pInt-I-hrGFP is an integrase expression plasmid, in which the CMV 
promoter drives simultaneous expression of integrase and GFP, through the action of an IRES. Independent expression vectors 
were cloned for the φC31, R4, and TP901-1 integrases. HygR, hygromycin resistance; AmpR, ampicillin resistance; IRES, inter-
nal ribosome entry site; CMV, cytomegalovirus immediate early promoter; Int, Integrase gene; GFP, green fluorescent protein; 
polyA, poly(A) addition site from simian virus 40.
attR
φC31 R4
TP
φC31 R4
TP
attBs attPs
HygR
pInt-I-hrGFP
(6847bp)
CMV
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tion effects. The φC31 integrase has also been shown to
function at efficiencies of ~50% for creation of transgenic
Drosophila  at inserted attP  sites [Groth, A.C., Fish, M.,
Nusse, R., and Calos, M.P., submitted]. This integrase is
therefore likely to be of use in construction of a wide range
of transgenic species.
We also demonstrated that the integrases of bacteri-
ophages φC31, R4, and TP901-1 performed efficiently in
creating intrachromosomal deletions and should be of
great value for manipulating mammalian genomes, both
in vitro and in vivo. The maximum observed deletion fre-
quencies presented here were in the range of 30–50%, but
this range probably underestimates the activity of these
integrases. The criteria used for sorting GFP-positive, inte-
grase-transfected cells may have included untransfected
cells. Following expansion of these cells, quantitative
analysis of chromosomal deletion frequency would be
depressed by the presence of cells that were never exposed
to integrase. However, even at the observed frequencies of
30–50%, the φC31, R4, and TP901-1 integrases constitute
efficient tools for the manipulation of mammalian chro-
mosomes. In the experiments reported here, the φC31, R4,
and TP901-1 integrases used were in their native prokary-
otic form, with no addition of an NLS. A φC31-NLS inte-
grase [41] may function significantly better, nearing
100%, in this chromosomal deletion assay, and addition
of an NLS may have a similar positive effect on the effi-
ciencies of the R4 and TP901-1 integrases. Such chromo-
somal deletion frequencies would make the φC31, R4,
and TP901-1 integrases equivalent to Cre recombinase
and valuable as molecular tools for mammalian chromo-
some engineering. Additional experiments will need to be
conducted in order to determine the efficiency of these
integrases in catalyzing chromosomal deletions in vivo.
These serine family site-specific phage integrases clearly
constitute new and valuable tools for genome
engineering.
Materials and Methods
Transgenic Animal Experiments
Vector construction
The  φC31 integrase gene was amplified to include the
NdeI restriction site from pTA-Int [1] by using the primers
"Native 5' NdeI (+)" (CGA CTA GTC ATA TGG ACA CGT
ACG CGG GTG CT) and "3' BamHI φC31" (AGC CGG
ATC CGG GTG TCT CGC TA). The pET11 vector (Nova-
gen, Madison, WI) received the amplified φC31 integrase
gene directionally inserted into NdeI and BamHI sites so
that the T7 promoter drove φC31 integrase mRNA produc-
tion (pET11φC31). The oligonucleotides BamHI-polyA-
top (GAT CGC GCC AAA AAA AAA AAA AAA AAA AAA
AAA AAA AAA CCG) and BamHI-polyA-bottom (GAT
CCG GTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TGG
CGC) were annealed, digested with BamHI, and inserted
into the BamHI site in pET11φC31 to create
pET11φC31polyA. The assay construct pEGFPB2 is based
on the vector pEGFP-N2 (Clontech, Palo Alto, CA). A lac
promoter to drive GFP expression in bacteria and codons
for the first 26 amino acids of β-galactosidase were cloned
into the NheI and HindIII sites within the multicloning
site of pEGFP-N2, placing it in frame with eGFP to create
Integrase-mediated chromosomal deletion Figure 3
Integrase-mediated chromosomal deletion. (A) Chromo-
somal deletion frequencies in 293-3BP cell lines calculated by 
quantitative PCR. The values represent the average of two 
experiments, with standard deviation bars. Cell lines were 
transfected with pφC31-IRES-hrGFP (dotted bars) or pR4-
IRES-hrGFP (dashed bars), GFP-positive cells were sorted 
and expanded, and genomic DNA was harvested and ana-
lyzed by qPCR. Deletion frequency was calculated as the 
ratio of attR junctions amplified to total vectors present 
(hygromycin resistance gene amplified), multiplied by 100. (B) 
Representative Southern blot of deletion reaction in cell line 
293-3BP6. Untransfected and Int-transfected cell lines are 
shown, with the expected intact (unex.) and Int-deleted 
bands for φC31 (φex), R4 (R4ex), and TP901-1 (TPex) indi-
cated. Twenty µg of genomic DNA were probed with a com-
mon 1.6 kb plasmid backbone fragment.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/79
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pCMVlacGFP. The attB fragment was released from pTA-
attB [1] with EcoRI, and the ends of the fragment were
blunted. The blunt attB fragment was inserted into pCM-
VlacGFP vector blunted at the DraIII restriction site. This
cloning of the attB with the TT core pointing towards the
GFP terminator sequence resulted in creation of the assay
vector pEGFPB2.
Nucleic acid preparations for microinjection
The φC31 integrase mRNA was transcribed from the vector
pET11φC31polyA using the mMessage mMachine
(Ambion, Austin, TX). φC31 RNA and DNA were purified
and diluted in microinjection TE (miTE) buffer (10 mM
Tris and 0.1 mM EDTA, pH 7.4) to reach a final concen-
tration of 3 ng/µl. For the injections 3 or 6 ng/µl solutions
of each nucleic acid were used.
PCR screening for integration
Standard embryo DNA retrieval technique for PCR was
employed [42]. The primers attBF2 (ATG TAG GTC ACG
GTC TCG AAG C) and attP1+ (TGG CGG CCG CTC TAG
AAC TA) were used to specifically amplify the wild type
attL junction in integrase-reacted pBCPB. A 175 bp prod-
uct will be amplified. For detection of mpsL1 integration
in embryos, a primary PCR using the primers attBF3 (CGA
AGC CGC GGT GCG) and mpsL1-R2 (GTA AAT GTT ATT
GCG GCT CT) was purified and used as a template in a
secondary PCR using attBF3 and the nested primer
mpsL1-R1 (TGA GGA GGA GCC TTA GCA AC). The sec-
ondary PCR amplifies a nested product of 208 bp. For
detection of the GFP transgene, the primers GFPfor (CTG
GAC GGC GAC GTA AAC GGC CAC) and GFPrev (GGC
GGA TCT TGA AGT TCA CCT TC) were used to specifically
amplify a 453 bp segment of the GFP transgene. The hFIX
positive cells were identified using the primers hFIXend
(CAC TTC TGG AGG CCA AGG TGG G) and attBRF2-com
(GCT TCG AGA CCG TGA CCT ACA TC), resulting in a
406 bp band being amplified. To identify φC31-mediated
transgenics, the primers hFIXend and attBR2 (TCA ACT
ACC GCC ACC TCG AC) were used, which provide a 508
bp product only if an intact attB is present. To detect the
presence of an attP segment in transgenic mice, the prim-
ers For4TRI (AAC TCA GTT GGG CTC AAT TCC) and the
Revr4TRI (CCA GTA GCT GAC ATT CAT CCG) were used
to amplify a specific 1559 bp product.
PCR detection of integration into pseudo attP sites
To detect integration at mpsL1 in pups, attBF3 and
mpsL1-R2 were used in a PCR reaction. Positive integrants
at mpsL1 resulted in a 513 bp product. To discover uni-
dentified pseudo attP sites, genomic DNA was digested
using: AvrII, NheI, SpeI and XbaI. The genomic digests were
ligated to produce circularized substrate for inverse PCR.
The  attL  junctions were amplified using attBF2 and
hFIXinvR1 (CAT CAA ATA CAG GGT GAC TGA TTC). A
nested reaction was then applied to increase specificity
using the primers attBF3 and hFIXinvR2 (CAA AGG GAA
ACA TAC GTC AG). Resulting bands were cloned and
sequenced.
Wild-type attP transgenic mice
The plasmid pTA-attP333 [4] carries the full length
TP901-1 attP site. The φC31 attP site was isolated as a
blunted SpeI fragment from pBCPB [1] and ligated into
the blunted AvaI site of pTA-attP333, creating the plasmid
pBI(-). The R4 attP site was isolated from the plasmid
pBCRattP64 [3] by digestion with PvuII and SnaBI and
blunt-ending with T4 polymerase. It was then ligated into
the DraIII pf pBI(-), creating the plasmid pTRI(+). pTRI(+)
was digested with BglII and HindIII to liberate a 1.9-kb
fragment containing the three attP sites. This triple-attP
fragment was gel isolated and purified using the QIAexII
gel extraction kit (Qiagen, Valencia, CA) and eluted with
miTE (10 mM Tris-HCl, 0.1 mM EDTA, pH7.4). DNA was
prepared to a concentration of 25 ng/µL. To eliminate
debris from the prep, the DNA was passed through a small
0.45 µm Millipore spin filter (Millipore, Billerica, MA).
DNA was transferred to the Stanford Transgenic Research
Facility for standard transgenic animal production by
microinjection.
Chromosomal Deletion Experiments
Vector construction
The assay plasmid for detecting chromosomal deletions was gen-
erated as follows. Plasmid pBB-B304-P333 has been described
[4] and will be referred to as pBB-TP(BP). This plasmid contains
the full-length TP901-1 attP and attB recognition sites flanking
the 3.5 kb lacZ gene. The 64 bp R4 attP site was generated by
kinasing and annealing the oligonucleotides 
5'-CCGGGCATGTTCCCCAAAGCGATACCACTTGAAGCAGTG
GTACTGCTTGTGGGTACACTCTGCGGGTGTAC-3' and 
5'-CCGGGTACACCCGCAGAGTGTACCCACAAGCAGTACCAC
TGCTTCAAGTGGTATCGCTTTGGGGAACATGC-3', followed by
ligation into the XmaI site of pBB-TP(BP), creating the plasmid
pBB-TP(BP)-R4(P). Into the SacII site of this plasmid, the 224 bp
φC31 attP site was cloned as an XbaI-ScaI fragment from plasmid
pBCPB+ [1], resulting in the plasmid pBB-TP(BP)-R4(P)-
φC31(P). Into the XhoI site of this plasmid, the 313 bp φC31 attB
site was cloned as an XhoI fragment released from pBCPB+, gen-
erating plasmid pBB-TP(BP)-R4(P)-φC31(BP). Into the BamHI
site of this plasmid, the 295 bp R4 attB site was ligated as an XhoI
fragment released from the plasmid pBC-R4PB [3], creating the
plasmid pBB-TP(BP)-R4(BP)-Phi(BP). Lastly, a 2.0 kb SalI-NruI
fragment from pEF [4], encoding the gene for hygromycin resist-
ance driven by the TK promoter, was cloned into the AgeI site of
pBB-TP(BP)-R4(BP)-φC31(BP), generating the assay plasmid
pBB-TP(BP)-R4(BP-φC31(BP)-Hyg, referred to as plasmid p3BP.
Each integrase was independently cloned into the expres-
sion plasmid pIRES-hrGFP-1a (Stratagene, La Jolla, CA).Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/79
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The TP901-1 integrase was cloned into the EcoRI-XhoI sites
of pIRES-hrGFP-1a as a 1.5 kb EcoRI-XhoI fragment from
pCS-TPInt [4], generating the plasmid pTP-I-hrGFP. A 1.4
kb EcoRI fragment from pTA-sre [3], containing the R4
integrase, was cloned into the EcoRI site of pIRES-hrGFP-
1a, creating the expression plasmid pR4-I-hrGFP. The
φC31 integrase was cloned from pCSI [1] as a 1.9 kb
blunted SpeI-BamHI fragment and ligated into the SmaI-
BamHI sites of pIRES-hrGFP-1a, to generate the vector pφ-
I-hrGFP. Each of these vectors expresses integrase under
the control of the CMV promoter, followed by an internal
ribosome entry site (IRES) and the humanized Renilla
reniformis GFP (hrGFP) open reading frame.
As a standard control for qPCR, the attR junction for each
integrase and a hygromycin gene region were cloned into
a single plasmid. Vector p3BP was transformed into E. coli
strain DH-Int, which expresses the φC31 integrase [1], in
order to generate a φC31-excised plasmid. The attR was
PCR amplified and TOPO-cloned into vector pCR2.1
(Invitrogen, Carlsbad, CA), creating the plasmid pTA-φex.
Next, the R4 attR was generated by intramolecular integra-
tion reaction in 293 cells co-transfected with p3BP and
pCMV-sre [3], creating p3BP-R4ex. The R4 attR junction
was PCR amplified from p3BP-R4ex with primers that
added SpeI sites to each end of the attR. The PCR product
was digested with SpeI and ligated into the SpeI site of
pTA-φex, creating plasmid pTA-φex-R4ex. The TP901-1
attR junction was generated by transforming p3BP into
DH-TPInts [4], generating plasmid p3BP-TPex. The
TP901-1 attR was then PCR amplified, with addition of
BamHI sites to each end. The PCR product was digested
with BamHI and ligated into the BamHI site of pTA-φex-
R4ex, creating the plasmid pTA-φex-R4ex-TPex. Next, a
region of human Rad52 gene was PCR amplified from 293
genomic DNA with primers that added ClaI sites to each
end. The PCR product was digested with ClaI and ligated
into the ClaI site of pTA-φex-R4ex-TPex, creating the plas-
mid pTA-3attR-Rad52. Finally, a portion of the hygromy-
cin gene encompassing the qPCR amplification region
was PCR amplified from p3BP, digested with XbaI, and
ligated into the XbaI site of pTA-3attR-Rad52, generating
the standard vector p3attR-Rad52-Hyg. This vector was
linearized with XcmI, purified, and serially diluted for use
in qPCR to generate a standard curve.
Cell lines
Plasmid p3BP was digested with XmnI to generate a linear
molecule. Five µg of linearized p3BP plasmid was electro-
porated into 293 cells using a Bio-Rad Gene Pulser accord-
ing to the manufacturer's recommendations. The cells
were then allowed to recover in nonselective Dulbecco's
modified eagle medium, supplemented with 9% FBS and
1% penicillin-streptomycin. After 24 h, the cells were
placed under selection using medium containing 200 µg/
ml hygromycin B (Calbiochem, La Jolla, CA). After 14–21
d under selection, single, well-isolated colonies were
picked and expanded. All cell lines were screened for the
presence of intact triple-attP and triple-attB sites by PCR
and by Southern analysis. Six 293-3BP cell lines were
selected for further analysis.
Chromosomal deletion assay
293-3BP cell lines were transfected with 5 µg of pInt-I-
hrGFP plasmid using Fugene 6 (Roche Applied Scientific,
Indianapolis, IN), according to manufacturer's protocol.
At 72 h post-transfection, GFP-positive cells were sorted
and collected using a MoFLoPs FACS machine, thus sort-
ing for cells that received integrase expression plasmid.
Approximately 15 d after sorting and expansion, cells
were harvested and genomic DNA was prepared using the
Blood and Cell Culture DNA Maxi Kit (Qiagen, Valencia,
CA).
Quantitative PCR analysis
Quantitative PCR on genomic DNA was performed using
the following primer/probe combinations: TP901 attR:
fwdTPex-qPCR 
5'-TGATGTTACTGCTGATAATGTAGATATCATAT-3', revT-
Pex-qPCR 5'-ATTAAAATTCACGGAAGAAAGCTTT-3',
TPEx-attR-probe 
5'-CGAGTTTTTATTTCGTTTATTTCAATCAAGGTAAATGC-
3'; Φ C31 attR: fwdPhiEx-qPCR 
5'-GGCTTCACGTTTTCCCAGGT-3', revPhiEx-qPCR 
5'-CCAGATGGGTGAGGTGGAGT-3', PhiEx-attR-probe 
5'-CTGGGGTAACCTTTGGGCTCCCCG-3'; R4 attR:
fwdR4ex-qPCR 5'-TCTCATGCATAGAAGGCCCG-3',
revR4ex-qPCR 5'-GGCTACACGGAGCAGGACC-3', R4ex-
attR-probe 
5'-CGATACCACTTGAAGCAGTGGTAGAAGGGCAC-3'.
The hygromycin resistance gene was also amplified as an
internal control for integrated p3BP vector, using the fol-
lowing primer/probe combination: fwdHyg-qPCR 
5'-CTCGGAGGGCGAAGAATCTC-3', revHyg-qPCR 
5'-GCAGCTATTTACCCGCAGGA-3', Hyg-probe 
5'-TCAGCTTCGATGTAGGAGGGCGTGG-3'. Each of
these probes was 5' labeled with the fluorophore 6-FAM
and 3' labeled with the quencher TAMRA.
In addition to the primers and probes described above,
PCR reagents used were from the TaqMan PCR Core Rea-
gent Kit (Applied Biosystems, Foster City, CA). Amplifica-
tion was performed in an ABI 7700 machine and the
results were analyzed using SDS v1.7 software (Applied
Biosystems). Each sample and standard was analyzed in
triplicate.
Southern analysis
Genomic DNA was digested overnight with HindIII.
Twenty µg of digested genomic DNA was loaded onto aReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/79
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0.6% TBE agarose gel and separated. The gel was depuri-
nated in 0.25 M HCl, denatured in 0.5 M NaOH, neutral-
ized in 0.5 M Tris-HCl (pH7.0), and transferred to an S&S
Nytran blotting membrane (Schleicher & Shuell, Keene,
NH) in 20X SSC transfer buffer. The membrane was
probed with a 1.6 kb fragment from the hygromycin
resistance gene or with a 1.6 kb genomic fragment from
8p22 encompassing φC31 human pseudo attP  site A
(hpsA) [2], both labeled with 32P by random primer
extension, using the Ready-To-Go DNA Labeling Kit (-
dCTP) (Amersham Pharmacia Biotech). Hybridization
occurred at 65°C for ~20 h in Church buffer (1% BSA, 1
mM EDTA, 0.5 M NaHPO4 pH 7.2, 7% SDS). Membranes
were washed in 2x - 0.2x SSC at 65°C. Membranes were
exposed to a phosphor screen and analyzed using a Storm
840 PhosphorImager (Molecular Dynamics, Sunnyvale,
CA). Southern blot quantification was performed using
Kodak 1D software.
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